Nilotinib, imatinib, and GIST therapy
Mené sur 647 patients atteints d'une tumeur stromale gastrointestinale métastatique ou non résécable, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du nilotinib par rapport à l'imatinib en traitement de première ligne
The discovery of driver mutations in gastrointestinal stromal tumours (GISTs) in the KIT or in PDGFRA oncogenes, and the subsequent incorporation of the tyrosine kinase inhibitor imatinib to the therapy of advanced disease, has resulted in remarkable therapeutic progress. Median overall survival of patients with metastatic tumours has risen from a few months to around 60 months in the last decade.1 Unfortunately, however, most patients will eventually develop resistance to imatinib after a median of 2 years, mainly due to the acquisition of secondary KIT and PDGFRA mutations.